Alessandra Oliveira Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alessandra Oliveira Silva has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Larissa Helena Torres
Department of Food and Drugs, Faculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, MG, Brazil
4 shared publications - Carla Speroni Ceron
Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Brazil
2 shared publications - Fernanda Borges de Araújo Paula
Universidade Federal de Alfenas
2 shared publications - Jéssyca Milene Ribeiro
Department of Food and Drugs School of Pharmaceutical Sciences Federal University of Alfenas Rua Gabriel Monteiro da Silva 700 37130-001 Alfenas MG Brazil
2 shared publications - Márcia Helena Miranda Cardoso Podestá
Universidade Federal de Alfenas
2 shared publications - Silvia Graciela Ruginsk
Department of Physiological Sciences, Biomedical Sciences Institute, Federal University of Alfenas, Alfenas, Brazil
2 shared publications
Latest Publications
- Open Access
- 1 April 2025
- Published by Lepidus Tecnologia in Brazilian Journal of Science
- Vol. 4 (4) , 1-12
Prevalence of anxiety, depression, and psychoactive substances use among pharmacy students in Minas Gerais: Impacts of the pandemic and the university environment
Mental disorders affect the population widely, and university students are considered a risk group due to the challenges of academic life. Furthermore, the COVID-19 pandemic has had a major impact on this population, intensifying symptoms of anxiety and depression. On the other hand, there is a high consumption of psychoactive substances among academics, which initially aim to minimize internal tensions, but can, in a chronic manner, harm health. Given this, a quantitative, descriptive, and cross-sectional study was carried out on the presence of anxiety and depression, as well as the use of psychoactive substances among pharmacy students at a public university in the interior of Minas Gerais. Two questionnaires were used for data collection, one for demographic and psycho-emotional assessment and another specific for anxiety and depression, known as the Hospital Anxiety and Depression Scale (HADS). The study population consisted of 350 academics. Of these, 69.43% were female, with an average age of 21.72 years. The data indicate that 39.14% of the interviewees had “probable” anxiety and 25.14% “probable” depression, affecting first-year and last-year students more prominently. In addition, there was a higher prevalence of anxiety in males. Depression, on the other hand, affected women more. Regarding the social context, it is observed that both the university and the COVID-19 pandemic increased the prevalence of anxiety and depression. Furthermore, 64.86% of the participants used psychoactive substances, with alcohol and anxiolytics and/or antidepressants being the most used. Thus, the impact of the university and the pandemic on mental illnesses is clear. Furthermore, the high use of psychoactive substances is worrying, as it can generate secondary damage. Therefore, it is suggested that educational measures for preventing psychoactive substance use, as well as improvements in programs related to mental health.
- 1 April 2025
- Published by Lepidus Tecnologia in Brazilian Journal of Science
- Vol. 4 (4) , 1-12
Open AccessPrevalence of anxiety, depression, and psychoactive substances use among pharmacy students in Minas Gerais: Impacts of the pandemic and the university environment
Mental disorders affect the population widely, and university students are considered a risk group due to the challenges of academic life. Furthermore, the COVID-19 pandemic has had a major impact on this population, intensifying symptoms of anxiety and depression. On the other hand, there is a high consumption of psychoactive substances among academics, which initially aim to minimize internal tensions, but can, in a chronic manner, harm health. Given this, a quantitative, descriptive, and cross-sectional study was carried out on the presence of anxiety and depression, as well as the use of psychoactive substances among pharmacy students at a public university in the interior of Minas Gerais. Two questionnaires were used for data collection, one for demographic and psycho-emotional assessment and another specific for anxiety and depression, known as the Hospital Anxiety and Depression Scale (HADS). The study population consisted of 350 academics. Of these, 69.43% were female, with an average age of 21.72 years. The data indicate that 39.14% of the interviewees had “probable” anxiety and 25.14% “probable” depression, affecting first-year and last-year students more prominently. In addition, there was a higher prevalence of anxiety in males. Depression, on the other hand, affected women more. Regarding the social context, it is observed that both the university and the COVID-19 pandemic increased the prevalence of anxiety and depression. Furthermore, 64.86% of the participants used psychoactive substances, with alcohol and anxiolytics and/or antidepressants being the most used. Thus, the impact of the university and the pandemic on mental illnesses is clear. Furthermore, the high use of psychoactive substances is worrying, as it can generate secondary damage. Therefore, it is suggested that educational measures for preventing psychoactive substance use, as well as improvements in programs related to mental health.
- 8 September 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (7) , e4119
Curcumin Prevents Renal Damage of l‐NAME Induced Hypertension in by Reducing MMP‐2 and MMP‐9
In the present study, we investigated whether curcumin administration would interfere with the main renal features of l‐NAME‐induced hypertension model. For this purpose, we conducted both in vitro and in vivo experiments to evaluate renal indicators of inflammation, oxidative stress, and metalloproteinases (MMPs) expression/activity. Hypertension was induced by l‐NAME (70 mg/kg/day), and Wistar rats from both control and hypertensive groups were treated with curcumin (50 or 100 mg/kg/day; gavage) or vehicle for 14 days. Blood and kidneys were collected to determine serum creatinine levels, histological alterations, oxidative stress, MMPs expression and activity, and ED1 expression. l‐NAME increased blood pressure, but both doses of curcumin treatment reduced these values. l‐NAME treatment increased creatinine levels, glomeruli area, Bowman's space, kidney MMP‐2 activity, as well as MMP‐9 and ED1 expression, and reduced the number of glomeruli. Curcumin treatment prevented the increase in creatinine levels, MMP‐2 activity, and reduced MMP‐2, MMP‐9, ED1, and superoxide levels, as well as increased superoxide dismutase activity and partially prevented glomeruli alterations. Moreover, curcumin directly inhibited MMP‐2 activity in vitro. Thus, our main findings demonstrate that curcumin reduced l‐NAME‐induced hypertension and renal glomerular alterations, inhibited MMP‐2 and MMP‐9 expression/activity, and reduced oxidative stress and inflammatory processes, which may indirectly impact hypertension‐induced renal outcomes.
- 8 September 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (7) , e4119
Curcumin Prevents Renal Damage of l‐NAME Induced Hypertension in by Reducing MMP‐2 and MMP‐9
In the present study, we investigated whether curcumin administration would interfere with the main renal features of l‐NAME‐induced hypertension model. For this purpose, we conducted both in vitro and in vivo experiments to evaluate renal indicators of inflammation, oxidative stress, and metalloproteinases (MMPs) expression/activity. Hypertension was induced by l‐NAME (70 mg/kg/day), and Wistar rats from both control and hypertensive groups were treated with curcumin (50 or 100 mg/kg/day; gavage) or vehicle for 14 days. Blood and kidneys were collected to determine serum creatinine levels, histological alterations, oxidative stress, MMPs expression and activity, and ED1 expression. l‐NAME increased blood pressure, but both doses of curcumin treatment reduced these values. l‐NAME treatment increased creatinine levels, glomeruli area, Bowman's space, kidney MMP‐2 activity, as well as MMP‐9 and ED1 expression, and reduced the number of glomeruli. Curcumin treatment prevented the increase in creatinine levels, MMP‐2 activity, and reduced MMP‐2, MMP‐9, ED1, and superoxide levels, as well as increased superoxide dismutase activity and partially prevented glomeruli alterations. Moreover, curcumin directly inhibited MMP‐2 activity in vitro. Thus, our main findings demonstrate that curcumin reduced l‐NAME‐induced hypertension and renal glomerular alterations, inhibited MMP‐2 and MMP‐9 expression/activity, and reduced oxidative stress and inflammatory processes, which may indirectly impact hypertension‐induced renal outcomes.
- Open Access
- 15 July 2023
- Published by IP Innovative Publication Pvt Ltd in Journal of Pharmaceutical and Biological Sciences
- Vol. 11 (1) , 18-25
Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review
Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.
- 15 July 2023
- Published by IP Innovative Publication Pvt Ltd in Journal of Pharmaceutical and Biological Sciences
- Vol. 11 (1) , 18-25
Open AccessTapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review
Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.
- 19 December 2022
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 15 (2) , 411-423
Protective Effects of Kefir Against Unpredictable Chronic Stress Alterations in Mice Central Nervous System, Heart, and Kidney
Kefir is a probiotic mixture with anxiolytic and antioxidant properties. Chronic stress can lead to anxiety disorders and increase oxidative damage in organs such as the heart and kidney. In this study, we examined whether kefir ameliorates the anxiety-like behavior of mice submitted to chronic unpredictable stress (CUS) by modulating brain-derived neurotrophic factor (BDNF) and corticosterone levels and whether kefir modifies the oxidative parameters in the heart and kidney of mice. Male Swiss mice received kefir (0.3 mL/100 g/day) or milk for 30 days (gavage). On the 10th day, the mice were submitted to CUS. Behavioral analysis was performed using the elevated plus maze and forced swimming tests. BDNF levels were analyzed in brain tissues. Heart and kidney superoxide dismutase (SOD), catalase, glutathione (GSH), thiobarbituric acid reactive substances (TBARS), 3-nitrotyrosine, metalloproteinase-2 (MMP-2), and plasma corticosterone were evaluated. Kefir reverted the CUS-induced decrease in the time spent in the open arms, the increase in grooming frequency, and decrease in the head dipping frequency, but not the reduced immobility time. CUS decreased the cerebellum BDNF levels and increased corticosterone levels, which were restored by Kefir. Neither catalase and SOD activities nor GSH, TBARS, 3-nitrotyrosine, and MMP-2 were modified by CUS in the heart. In the kidney, CUS increased 3-nitrotyrosine and MMP-2. Kefir increased the antioxidant defense in the heart and kidney of control and CUS mice. These results suggest that kefir ameliorated CUS-induced anxiety-like behavior by modulating brain BDNF and corticosterone levels. Kefir also increased the antioxidant defense of mice heart and kidney.
- 19 December 2022
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 15 (2) , 411-423
Protective Effects of Kefir Against Unpredictable Chronic Stress Alterations in Mice Central Nervous System, Heart, and Kidney
Kefir is a probiotic mixture with anxiolytic and antioxidant properties. Chronic stress can lead to anxiety disorders and increase oxidative damage in organs such as the heart and kidney. In this study, we examined whether kefir ameliorates the anxiety-like behavior of mice submitted to chronic unpredictable stress (CUS) by modulating brain-derived neurotrophic factor (BDNF) and corticosterone levels and whether kefir modifies the oxidative parameters in the heart and kidney of mice. Male Swiss mice received kefir (0.3 mL/100 g/day) or milk for 30 days (gavage). On the 10th day, the mice were submitted to CUS. Behavioral analysis was performed using the elevated plus maze and forced swimming tests. BDNF levels were analyzed in brain tissues. Heart and kidney superoxide dismutase (SOD), catalase, glutathione (GSH), thiobarbituric acid reactive substances (TBARS), 3-nitrotyrosine, metalloproteinase-2 (MMP-2), and plasma corticosterone were evaluated. Kefir reverted the CUS-induced decrease in the time spent in the open arms, the increase in grooming frequency, and decrease in the head dipping frequency, but not the reduced immobility time. CUS decreased the cerebellum BDNF levels and increased corticosterone levels, which were restored by Kefir. Neither catalase and SOD activities nor GSH, TBARS, 3-nitrotyrosine, and MMP-2 were modified by CUS in the heart. In the kidney, CUS increased 3-nitrotyrosine and MMP-2. Kefir increased the antioxidant defense in the heart and kidney of control and CUS mice. These results suggest that kefir ameliorated CUS-induced anxiety-like behavior by modulating brain BDNF and corticosterone levels. Kefir also increased the antioxidant defense of mice heart and kidney.